Upload
coleen-glenn
View
214
Download
0
Tags:
Embed Size (px)
Citation preview
Legends for supplementary figures
Fig s1. A: Western blot showing the suppression of SRp20 expression
by Dox induction of SRp20 siRNAs in SKOV3 sublines. B: Cell growth
curve. Shown are the results of three independent experiments. Error
bars represent standard error. C: Left panel, sample micrographs of
Hoechst 33342-stained nuclei of SKOV3 subline cells. Arrow indicates
the typical apoptotic cells. Right panel, Quantitation of apoptotic cells.
Fig s2. A: Western blot showing the suppression of SRp20 expression
by Dox induction of SRp20 siRNAs in IGROV1 sublines. B: Cell growth
curve of IGROV1 sublines. C: Left panel, sample micrographs of
Hoechst 33342-stained nuclei of IGROV1 subline cells. Arrow indicates
the typical apoptotic cells. Right panel, Quantitation of apoptotic cells.
Dox
SKOV3β-actin
SRp20
SRp20si1 SRp20si2- + - +
LUCsi- +
Fig s1
A
B
C
SKOV3/LUCsi
SKOV3/SRp20si1
SKOV3/SRp20si2
Without Dox WithDox
% Knockdown 67 91
SRp20si1 SRp20si2LUCsi
- + - +Dox - +
β-actin
SRp20IGROV1
Fig s2
A
B
CWithout Dox With Dox
IGROV1/LUCsi
IGROV1/SRp20si1
IGROV1/SRp20si2
% Knockdown 47 79
† Evaluable cases require at least two satisfactory cores with staining for either PTB or SRp20.
Disease Status
Satisfactory Cores per Case Evaluable
Cases †TotalCases
Histologic Subtype for Evaluable Cases
0 1 2 3 Mucinous Serous Clear Cell EndometrioidPoorly
Differentiated
PTB staining
Benign 12 13 14 3 17 42 15 2 0 0 0
Borderline/LMP 0 12 18 31 49 61 25 23 0 1 0
Invasive 1 2 11 56 67 70 26 9 30 0 2
Total 13 27 43 90 133 173 66 34 30 1 2
SRp20 staining
Benign 23 11 5 3 8 42 7 1 0 0 0
Borderline/LMP 2 14 15 30 45 61 22 22 0 1 0
Invasive 2 4 6 58 64 70 25 9 28 0 2
Total 27 29 26 91 117 173 54 32 28 1 2
Table s1. Distribution of Evaluable and Total Cases by Disease Status, Number of Satisfactory Cores and Histologic Subtype in the Disease Status TMA Stained for PTB or SRp20.
Disease status
PTB † SRp20 ‡
All Negative
MixedAll
PositiveTotal
All Negative
MixedAll
PositiveTotal
Benign 7 (46.7) 5 (33.3) 3 (20.0) 15 1 (14.3) 3 (42.9) 3 (42.9) 7
Borderline/LMP 8 (32.0) 7 (28.0) 10 (40.0) 25 0 (0) 9 (40.9) 13 (59.1) 22
Invasive 2 (7.7) 5 (19.2) 19 (73.1) 26 0 (0) 2 (8.0) 23 (92.0) 25
Total 17 17 32 66 1 14 39 54
Table s2. Differential expression of PTB or SRp20 in the mucinous ovarian tumors in the Disease Status TMA
Percentage within each staining category is provided in parentheses. Statistical significance was evaluated using Fisher’s exact test for data in 2 x 2 tables [43]; and the Mehta and Patel version of Fisher’s exact test for data in R x C tables [44]. † p=0.0074 for overall test; p=0.0015 for benign vs. invasive; p>0.05 for benign vs. borderline/LMP; p=0.036 for borderline/LMP vs. invasive. ‡ p=0.0036 for overall test; p=0.012 for benign vs. invasive; p>0.05 for benign vs. borderline/LMP; p=0.014 for borderline/LMP vs. invasive.
Table s3. Distribution of Evaluable and Total Cases by Tumor Stage, Number of Satisfactory Coresand Histologic Subtype in the Tumor Stage TMA Stained for PTB or SRp20
† Evaluable cases require at least two satisfactory cores with staining for either PTB or SRp20.
Tumor Stage
Satisfactory Cores per Case Evaluable
Cases †TotalCases
Histologic Subtype for Evaluable Cases
0 1 2 3 Endometrioid SerousMixed
Epithelial
PTB staining
Stage I 0 0 12 34 46 46 27 15 4
Stage II 0 3 6 23 29 32 10 19 0
Stage III 0 0 10 47 57 57 26 29 2
Stage IV 1 2 11 26 37 40 13 23 1
Total 1 5 39 130 169 175 76 86 7
SRp20 staining
Stage I 1 4 13 28 41 46 25 12 4
Stage II 1 2 10 19 29 32 10 19 0
Stage III 0 0 12 45 57 57 26 29 2
Stage IV 1 5 12 22 34 40 12 21 1
Total 3 11 47 114 161 175 73 81 7
Categorized stagePTB † SRp20 ‡
Low High Total Low High Total
Early stage (I+II) 50 (66.7%) 25 (33.3%) 75 42 (60.0%) 28 (40.0%) 70
Advanced stage (III+IV) 45 (47.9%) 49 (52.1%) 94 32 (35.2%) 59 (64.8%) 91
Total 95 74 169 74 87 161
Table s4. Intensity of PTB or SRp20 staining in the Ovarian Cancer Stage TMA
Statistical significance was evaluated using Fisher’s Exact test [43]. Staining intensity was categorized as low (score<2.5) or high (score2.5). † p=0.019 for comparison of early stage vs. advanced stage.‡ p=0.002 for comparison of early stage vs. advanced stage.